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Chemical Modification of DNA with Muta-
Carcinogens. III. Reductive Alkylation of
DNA with Mitomycin C.
by Yuichi Hashimoto* and Koichi Shudo*
Mitomycin C (MMC) binds to DNA after its reductive activation by catalytic hydrogenation with Pd on
charcoal. Three modified nucleotides, named MG-1, MG-2, and MA, were isolated from the modified DNA
after enzymatic hydrolysis to 5'-nucleotides. The structures of these modified nucleotides were deduced
fromtheir1H-NMR andUVspectra, andfromstudiesofthechemicallytransformedderivatives(hydrolysis,
methylation, diazotization, and thioketonization). These three modified nucleotides were concluded to be
1,2-trans-2,7-diamino-1-(N2-deoxyguanylyl)mitosene (MG-1), 2,7-diamino-1-(06-deoxyguanylyl)mitosene
(MG-2) and2,7-diamino-l-(N-deoxyadenylyl)mitosene (MA). Thesamemodifiednucleotides wereidentified
in DNA extracted from the livers of rats treated with MMC.
Introduction
Mitomycin C (MMC) is a potent antibiotic and is also
used clinically as an antitumor agent. Recently (1), a
revised structure ofMMC, the antipode ofthe structure
reported previously, was proposed (I). It is well estab-
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lished that MMC requires reductive activation to be-
come analkylatingagent ofDNA(2). The action ofMMC
as a bioreductive alkylating agent of DNA is believed
to be, at least in part, responsible for its effectiveness
as an antitumor agent. Bifunctional alkylation of DNA
leading to crosslinking of the two strands was consid-
ered to be the direct cause of the cytotoxicity of the
drug (3), although the monofunctional attachment, which
occurs 10 to 20 times more frequently than the cross-
linking, has also been implicated as biologically signif-
icant damage to DNA (2). Elucidation of molecular
aspects of this alkylation reaction of DNA by MMC
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should provide basic information for the development
of more effective antitumor agents. Recently, Moore
suggested that positions 1 and 10 of MMC are binding
sites of MMC with DNA (4), though no unambiguous
evidenceforthechemicalstructureofthemodified DNA
has yet been obtained. Very recently, we reported (5)
the alkylation of 5'-guanylic acid by reductively acti-
vated MMC and showed the structure of MMC-bound
5'-guanylic acid to be 1,2-cis-2,7-diamino-1-(5'-guany-
lyl)mitosene (Fig. 1). The other nucleic acid derivatives
modified with MMC are uridyl derivatives (Fig. 1) re-
ported by Tomasz and Lipman (6), but the products
were obtained by reaction of MMC and uridylic acid
derivatives under acidic conditions and without reduc-
tive activation of MMC.
In this article, we review the isolation and structural
identification of monofunctional alkylation products of
DNA obtained with reductive activated MMC (7,8). DNA
was modified chemically by catalytic reduction, as well
as in vivo in male Wistar rats (8).
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FIGURE 1. Structures ofmodified ribonucleotides: (1) R1 =uridyl-5',
R2=H; (2) R1=R2=uridyl-5'-; (3) Rl=P(OH)OOP(OH)OO-
(uridyl-5')-, R2=H; (4) R1=guanyl-5'-, R2=H.HASHIMOTO AND SHUDO
Structure of the Nucleotides
Modified with MMC
MMC binds to DNA only after reductive activation
under neutral conditions. We used catalytic hydrogen-
ation with 5% Pd on charcoal and H2 gas for reductive
activation of MMC. About one molecule of MMC was
bound per 200-300 nucleotides in DNA, as estimated
from the UV spectrum ofthe modified DNA. Analysis
of an enzymatic hydrolysate ofthe modified DNA showed
the presence of three modified nucleotides, MG-1, MG-
2, and MA. More than 80% of the binding of MMC to
DNA could be accounted for by the formation ofMG-1,
MG-2, and MA.
The UV spectra of MG-1, MG-2, and MA have ab-
sorption maxima at ca. 310 nm, suggesting that these
modified nucleotides contain amitosenemoiety, because
the mitosene chromophore has an absorption maximum
at 310 nm (9).
MG-1, MG-2, and MA were hydrolyzed completely by
treatment with 1 N HCl. MG-1 gave guanine (45%) and
xanthine (15%), and MG-2 gave guanine quantitatively,
suggesting that MG-1 and MG-2 are deoxyguanylic acid-
MMC adducts. MA gave adenine quantitatively, sug-
gesting that MA is a deoxyadenylic acid-MMC adduct.
When these modified nucleotides were treated with
alkaline phosphatase, less polar products (probably the
corresponding nucleosides) were obtained quantita-
tively. This finding and the observation that these nu-
cleotides were all resistant to phosphodiesterase suggest
that these compounds have a monophosphate group at
the 5'-position of 2'-deoxyribose.
1H-NMR spectra were obtained in DMSO-d6-
CF3COOD. The use of completely anhydrous solvent
and exchange of hydrogen of NH and OH made it pos-
sible to assign all the signals. Assignment of proton
signals was performed by homonuclear decoupling ex-
periments and by comparing the spectra obtained with
those of model compounds such as mitosenes and nu-
cleotides. The results are shown in Figure 2.
The 1H-NMR spectra and the results ofhydrolysis of
MG-1, MG-2, and MA suggest that the binding sites of
nucleic acid base moieties are at heteroatoms of the
purine rings. These modified nucleotides were hydro-
lyzed with 1 N HCI after methylation with trimethyl-
sulfoxoniumiodide in DMSO. Both MG-1 and MG-2 gave
guanine (4-10%), 3-methylguanine (1%), 1-methylguan-
ine (2-3%), and 7-methylguanine (4-5%). MG-1 also gave
xanthine (4%). MA gave adenine (trace), 1-methylad-
enine (14%), 3-methyladenine (11%), and 7-methylad-
enine (0.5%). In all cases, some other products were
observed, but not 06-methylguanine from MG-2 and not
N6-methyl- or N6,N6-dimethyladenine from MA. These
results suggest that the methylated positions (the 1-,
3-, and 7-positions) and the glycosylated position (the
9-position) ofthe purine rings are not the binding sites.
Therefore, the binding site of MA is at the N6 atom of
adenine, and those of MG-1 and MG-2 are at the O6 or
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FIGURE 2. Structures of MA, MG-1, and MG-2 and their 'H-NMR
(8 from TMS in DMSO-d6 containing 5% of CF3COOD).,
N2 atom ofguanine. For unambiguous determination of
the binding sites of the guanine moieties of MG-1 and
MG-2, the guanine moieties were chemically trans-
formed. Acid hydrolysis ofMG-1 and MG-2 after treat-
ment with P2S5 gave 6-thioguanine from MG-1 (30%),
but this was not obtained from MG-2. This suggests
that the 06 atom of the guanine moiety is blocked in
MG-2 but not in MG-1. In addition, MG-1 and MG-2
werehydrolyzed withHCIaftertreatmentwithNaNO2.
The free amino group of guanine should be diazotized
easily. Guanine (10%) togetherwith xanthine (20%) was
obtained from MG-1, but onlyxanthine (30%), notguan-
ine, from MG-2. From these results, the binding sites
ofMG-1 and MG-2 were determined to be at the N2 and
06 atom, respectively. Therefore, the structures ofMG-
1, MG-2, and MA are as shown in Figure 2 (7,8). The
structure of MG-2 was confirmed by Tomasz et al (9).
They isolated MG-2 from the hydrolysate of the dinu-
cleotide GpC modified with reductively activated MMC,
and determined the configuration at positions 1 and 2
to be trans.
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Modification of DNA in Vivo
DNA extracted from the liver of a rat treated with
MMC was modified with MMC. About one molecule of
MMC was bound per 1-2 x 104 nucleotides, as esti-
mated from the UV spectrum ofthe modified DNA (ra-
tio ofabsorbance at 260 nm to that at 310 nm). Enzymatic
hydrolysis gave MG-1, MG-2, and MA in a ratio of 1:5:2
(Fig. 3) (8). The yields of these three modified nucleo-
tides accounts for most ofthe MMC bound to DNA; the
amounts of other nucleotides modified with MMC, if
any, were very small. MMC bound preferentially to
guanine in DNA, especially at the 06 atom.
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Reaction Mechanism
The mechanism of formation of these modified nu-
cleotides was not established unequivocally, but in view
of previous results, we propose that the mechanism of
the reaction is as shown in Figure 4. MMC is reduced
to the corresponding hydroquinone (MMC-H2). This re-
duction enhances the electron-donating ability and aids
elimination ofthe 9a-methoxy group. In the demethoxy
product(demethoxy-MMC-H2), cleavageoftheaziridine
ring is facilitated: position 1 is now benzylic and is ac-
tivated by many electron-donating groups. The carbon-
ium ion (MS-cation) formed by the opening of the
UV of MG-2
UV of Peak I
300 400 nm
FIGURE 3. HPLC of hydrolysate of DNA extracted from the liver of a rats treated with MMC (a) and the UV spectra of peak I and MG-2
(b). Column: Polygosil 5C18, 4.6 mm ID x 25 mm; solvent: CH3CN(10%)-0.3%NH4Cl aq.(90%); flow rate: 0.8 mL/min.
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FIGURE 4. Reaction mechanism of modification of nucleic acids by reductively activated MMC.
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aziridine ring has a planar structure which can inter-
calate into DNA and can thus approach position 2 or 6
of the purine bases. Covalent binding then occurs be-
tween position 1 ofmitosene and heteroatom at position
2 or 6 of the purine bases. The products might be oxi-
dized by excess MMC or MMC derivatives (or by other
cellular components in vivo and in vitro) or during the
work-up procedures to give MG-1, MG-2, and MA.
Conclusion
The structures of the nucleotides modified with re-
ductively activated MMC were determined to be as
shown in Figure 2. The reaction established chemically
occurs both in vitro and in vivo. The present findings
represent a first step in understanding the molecular
basis ofthe action ofMMC as a bioreductive alkylating
agent. The reductive activation and the mode of mod-
ification of nucleotides in DNA must, at least in part,
play a role in the carcinostatic or carcinogenic mecha-
nisms of MMC. These findings may contribute to the
development of more effective antitumor-active MMC
derivatives.
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